ACST Acasti Pharma
- 3.0300
- +0.1799+6.31%
- 2.9500
- -0.0800-2.64%
Acasti Pharma News
Acasti Pharma (ACST) Gets a Buy From Craig-Hallum
Express News | Acasti Pharma Q3 EPS $(0.21) Up From $(0.52) YoY
Acasti Pharma 3Q Loss/Shr 21c >ACST
Acasti Pharma 3Q Loss/Shr 21c >ACST
Acasti Pharma: Projected Cash Runway Extends Into Second Calendar Qtr 2026 >ACST
Acasti Pharma: Projected Cash Runway Extends Into Second Calendar Qtr 2026 >ACST
Acasti Pharma: Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, on Track for NDA Submission Timeline >ACST
Acasti Pharma: Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, on Track for NDA Submission Timeline >ACST
Acasti Pharma Initiated at Buy by Craig-Hallum
Acasti Pharma Initiated at Buy by Craig-Hallum
Express News | Craig-Hallum Initiates Coverage On Acasti Pharma With Buy Rating, Announces Price Target of $6
Acasti Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/07/2024 130.77% Craig-Hallum → $6 Initiates Coverage On → Buy 02/15/2023 -3.85% EF Hutton → $2.5 Reiter
Acasti Announces Poster Detailing Its GTX-104 STRIVE-ON Trial
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of
Acasti Pharma GAAP EPS of -$0.43
Acasti Pharma Cash and Cash Equivalents as of Sept 30 Totaled $27M >ACST
Acasti Pharma Cash and Cash Equivalents as of Sept 30 Totaled $27M >ACST
Acasti Pharma 2Q Loss $3.3M >ACST
Acasti Pharma 2Q Loss $3.3M >ACST
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 Completed $7.5 Million Private Placement Equity Financing led by ADAR1 Partners, LP, Providing Funding Well
Aker BioMarine Gains Krill Assets From Acasti Pharma in $3.1 Million Settlement Deal
Aker BioMarine (AKBM.OL) said Tuesday it acquired certain assets from late-stage specialty pharma company Acasti Pharma as part of the latter's contractual settlement of $3.1 million to the group. The
Express News | Acasti Announces Dosing Of First Patient In GTX-104 STRIVE-ON Trial
Analysts Offer Insights on Healthcare Companies: Acasti Pharma (ACST), Omnicell (OMCL) and MoonLake Immunotherapeutics (MLTX)
Optimistic Outlook for Acasti Pharma's GTX-104: Assessing Buy Rating and Potential Impact on Aneurysmal Subarachnoid Hemorrhage Treatment
Acasti Pharma Inc Files For Shelf Of Up To 6.6M Common Shares By Selling Stockholders
Acasti Pharma Inc Files For Shelf Of Up To 6.6M Common Shares By Selling Stockholders
Analysis
Price Target
No Data
